{"id":"NCT03482635","sponsor":"Boehringer Ingelheim","briefTitle":"BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis","officialTitle":"A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI655130 (SPESOLIMAB) Induction Therapy in Patients With Moderate-to-severely Active Ulcerative Colitis Who Have Failed Previous Biologics Therapy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-03-27","primaryCompletion":"2020-05-18","completion":"2020-05-18","firstPosted":"2018-03-29","resultsPosted":"2021-06-11","lastUpdate":"2021-06-11"},"enrollment":98,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Colitis, Ulcerative"],"interventions":[{"type":"DRUG","name":"Spesolimab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1- Placebo Group","type":"EXPERIMENTAL"},{"label":"Group 2- Small Dose Group","type":"EXPERIMENTAL"},{"label":"Group 3- Medium Dose Group","type":"EXPERIMENTAL"},{"label":"Group 4 - High Dose Group","type":"EXPERIMENTAL"}],"summary":"This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are\n\n* to prove the concept of clinical activity of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments and to identify efficacious and safe dose regimens in Part 1 (Phase II)\n* to confirm efficacy and safety of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments in Part 2 (Phase III)\n* To provide, along with induction study 1368-0018 and the run-in cohort of 1368-0020, the target population to be evaluated in study 1368-0020.","primaryOutcome":{"measure":"Proportion of Patients With Clinical Remission at Week 12","timeFrame":"At week 12.","effectByArm":[{"arm":"Placebo","deltaMin":0,"sd":null},{"arm":"300 mg Spesolimab (BI 655130) SD","deltaMin":0.042,"sd":null},{"arm":"450 mg Spesolimab (BI 655130) q4w","deltaMin":0.087,"sd":null},{"arm":"1200 mg Spesolimab (BI 655130) q4w","deltaMin":0.071,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG003","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":54,"countries":["United States","Austria","Belgium","Canada","Germany","Italy","Japan","Poland","Russia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["39216969"],"seeAlso":["http://www.mystudywindow.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":23},"commonTop":["Colitis ulcerative","Anaemia","Nasopharyngitis","Rash","Headache"]}}